Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome.

about

Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome.

Item

http://www.wikidata.org/entity/Q41807158

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome.

@en

type

Item

label

Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome.

@en

prefLabel

Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome.

@en

P1476

Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome

@en

P2093

Andreas Kruger

http://www.w3.org/2001/XMLSchema#string

David Alan

http://www.w3.org/2001/XMLSchema#string

Jiri Vejvoda

http://www.w3.org/2001/XMLSchema#string

Jitka Segethova

http://www.w3.org/2001/XMLSchema#string

Petr Ostadal

http://www.w3.org/2001/XMLSchema#string

P2860

Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design

The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized

Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)

A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial

Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiba

Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

Postprocedural low molecular weight heparin in patients at high risk of subacute stent thrombosis

Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology

A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study

Comparative pharmacokinetics of LMWHs.

P304

175-178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19343162

http://www.w3.org/2001/XMLSchema#string

P932

2663480

http://www.w3.org/2001/XMLSchema#string